Skip to content
thispeptide

RoenRx

RoenRx combines an independent clinical network, insurance coordination and compounded medication access. Its longer-plan price and FDA warning deserve closer attention than the broad access promise.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

A named clinical network is useful, but obtain the actual prescriber, pharmacy and follow-up plan before considering treatment. The public ingredient comparisons should not be taken as evidence that a compound matches an approved brand.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

FDA warning letter on record: Letter 728293 · June 2026

The current terms name Roen Health, Inc. as the platform operator. Its clinical service is separate from the technology company. On the current weight-loss page, a cash-pay compounded semaglutide offer sits apart from insurance-dependent brand access. A tirzepatide program is also described in the terms. A prescription depends on the treating clinician rather than the platform alone.

What RoenRx prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)Price not published
    • Injection (brand)Price not published
  • TirzepatideFDA-approved
    • Injection (brand)Price not published

Brand prescriptions depend on insurance coverage and clinical eligibility. Compounded options lack FDA approval and have separate formulations. Ask about dose selection, contraindications and reassessment if the medicine is ineffective or poorly tolerated.

Who prescribes

A licensed clinician

The terms identify Bruno Health professional association, Outlast Health and affiliated medical groups as the clinical network. The assigned clinician and dispensing pharmacy are not individually identified in the public offer. Ask for the treating practice, state license and pharmacy before deciding whether the arrangement suits your needs.

The public pathway starts with eligibility questions and provider review of the responses. Online tools support refills and communication with the care team. Broad continuing-access promises do not establish a scheduled video visit or a guaranteed clinical response time. Coaches are not necessarily licensed dietitians under the terms.

Are labs required?

Testing plan and charges unconfirmed

The payment policy permits charges for diagnostic testing recommended by a provider. A universal baseline panel, repeat-testing schedule and included laboratory allowance were not established. Confirm which tests apply to your prescription and who receives the results.

Ready to start with RoenRx?

Prices and plans are set on the seller's own site.

What it claims, and what it cites

FDA sent RoenRx a June 2026 warning letter after reviewing its website in March 2026. The agency objected to pictured labels implying that the brand compounded the medicine. It also challenged ingredient comparisons that implied FDA evaluation or approval of compounded products. The letter concerns that dated website review; no FDA closeout was confirmed.

How it bills

The semaglutide card advertises an as-low-as $151 monthly equivalent when purchased quarterly. It does not establish a flexible one-month charge. The $25 brand headline depends on insurance and is not a universal cash price. Membership terms distinguish general access fees from specific medication-inclusive programs. Memberships renew automatically until canceled through the account. Current-period membership and consultation charges are described as nonrefundable. Prescription returns are also restricted after pharmacy fulfillment. Confirm the cancellation deadline and the full charge before accepting a longer plan.

For and against

  • For: Clinical network identified
  • For: Provider-review pathway described
  • For: Account cancellation instructions published
  • Against: Flexible monthly charge unresolved
  • Against: Individual pharmacy assignment unclear
  • Against: Dated FDA warning without confirmed closeout

The evidence behind what it sells

Right for

A patient prepared to confirm the actual clinical and pharmacy assignments and obtain a written longer-plan quote.

Look elsewhere if

Someone seeking a verified one-month cash price or assuming a compounded medicine carries the approval of a branded product.

Other sellers for weight

RoenRx

Frequently asked questions

Who provides medical care?
Terms identify Bruno Health professional association, Outlast Health and affiliated practices. Ask which clinician and pharmacy will handle the actual prescription.
Does the headline establish a monthly plan?
No. The $151 semaglutide figure is qualified by a quarterly purchase, and the brand headline depends on insurance.
Was the FDA matter closed?
A closeout was not confirmed. The warning describes historical website representations and should be read with its date and precise scope.

Sources

  • Current services and access claims
  • Insurance-dependent brand offers and quarterly semaglutide headline
  • Platform and independent clinical group terms
  • Membership billing, cancellation and refund policy
  • FDA warning letter 728293
  • Clinical group and telehealth consent

See what RoenRx prescribes today

RoenRx sets its own prices, plans and the states it serves. Check them before you start.

Written by Leah Garner from RoenRx’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.